Neurocrine Biosciences (NBIX) Long-Term Deferred Tax (2011 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Long-Term Deferred Tax of $8.9 million for Q2 2026, down 98.34% year-over-year from $536.8 million in Q2 2025, and down 97.67% on a QoQ basis from $381.4 million in Q1 2026.
Neurocrine Biosciences (NBIX) Long-Term Deferred Tax (2011 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Long-Term Deferred Tax for 8 years, with the latest figure at $8.9 million in Q2 2026.
- Long-Term Deferred Tax for Q2 2026 came in at $8.9 million, down 98.34% year-over-year; the trailing twelve-month figure through Jun 2026 was $8.9 million (down 98.34% YoY), and the FY2025 annual result was $320.3 million, down 34.05% from the prior year.
- Long-Term Deferred Tax slipped to $8.9 million in Q2 2026, from $381.4 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $536.8 million in Q2 2025 and troughed at $8.9 million in Q2 2026.
- A 5-year average of $366.3 million and a median of $373.3 million in 2024 frame the typical range for Long-Term Deferred Tax.
- The widest annual swing landed in 2024, when Long-Term Deferred Tax jumped 33.95%; it then plunged 98.34% in 2026.
- A 5-year view of Long-Term Deferred Tax shows it stood at $305.9 million in 2022, then advanced by 18.54% to $362.6 million in 2023, then jumped by 33.95% to $485.7 million in 2024, then plunged by 34.05% to $320.3 million in 2025, then plunged by 97.22% to $8.9 million in 2026.
- Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $8.9 million in Q2 2026, $381.4 million in Q1 2026, and $320.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Alkermes | 8.09 Bn | 7.43 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.90 Mn |
| Mar 31, 2026 | 381.40 Mn |
| Dec 31, 2025 | 320.30 Mn |
| Sep 30, 2025 | 368.50 Mn |
| Jun 30, 2025 | 536.80 Mn |
| Mar 31, 2025 | 499.40 Mn |
| Dec 31, 2024 | 485.70 Mn |
| Sep 30, 2024 | 454.40 Mn |
| Jun 30, 2024 | 419.50 Mn |
| Mar 31, 2024 | 378.20 Mn |
| Dec 31, 2023 | 362.60 Mn |
| Sep 30, 2023 | 383.20 Mn |
| Jun 30, 2023 | 379.00 Mn |
| Mar 31, 2023 | 337.40 Mn |
| Dec 31, 2022 | 305.90 Mn |
| Sep 30, 2022 | 319.40 Mn |
| Jun 30, 2022 | 328.40 Mn |
| Mar 31, 2022 | 325.30 Mn |
| Dec 31, 2021 | 315.10 Mn |
| Sep 30, 2021 | 310.40 Mn |